Related Experiment Video
Updated: May 20, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Pharmacoeconomic issues in psoriatic arthritis.
Ignazio Olivieri1, Salvatore D'Angelo, Carlo Palazzi
1Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy. ignazioolivieri@tiscalinet.it
The Journal of Rheumatology. Supplement
|July 4, 2012
Summary
Tumor necrosis factor-α (TNF-α) blockers offer new hope for psoriatic arthritis, effectively reducing inflammation and joint damage. Despite high costs, these advanced therapies are proving cost-effective for managing psoriatic disease.
Area of Science:
- Rheumatology
- Immunology
- Pharmacoeconomics
Background:
- Psoriatic arthritis therapies were previously inadequate for preventing joint damage.
- Nonsteroidal anti-inflammatory drugs and traditional disease-modifying antirheumatic drugs offer symptomatic relief but do not halt structural progression.
Purpose of the Study:
- To evaluate the impact of tumor necrosis factor-α (TNF-α) blocking agents on psoriatic arthritis.
- To assess the cost-effectiveness of TNF-α blockers in managing psoriatic disease.
Main Methods:
- Review of existing literature on psoriatic arthritis treatments.
- Analysis of pharmacoeconomic data for TNF-α blocking agents.
Main Results:
- TNF-α blockers significantly reduce inflammation, improve function, and inhibit joint damage in psoriatic arthritis.
- These agents enhance patient quality of life.
- Pharmacoeconomic studies indicate cost-effectiveness for both skin and musculoskeletal manifestations of psoriatic disease.
Conclusions:
- TNF-α blocking agents represent a significant advancement in psoriatic arthritis treatment.
- Despite high costs and accessibility issues, these therapies provide good value for money.
- Further research into cost-effective strategies for broader access is warranted.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...